Neuropace (NPCE) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.10
- Estimate
- -$0.08
- Surprise
- -27.1%
- Revenue (period 2026-09-30)
- $23.1M
- Score at report (before → after)
- 4.0 → 4.1/10
Revenue source: xbrl.
How the report landed
Neuropace (NPCE) reported a wider loss than forecast — adjusted EPS of -$0.10 against the -$0.08 estimate (a 27.1% shortfall). TrendMatrix's engine moved from Sell (4.0/10) to Hold at 4.1/10 after the report — the engine's score rose despite the miss.
Coverage in the report window
- 12 Health Care Stocks Moving In Friday's Intraday Session — benzinga, 2026-11-13
- Multiple Analysts Downgrade NeuroPace Following Q3 Revenue Miss — fiscal.ai, 2026-11-13
- Keybanc Maintains Overweight on NeuroPace, Lowers Price Target to $14 — benzinga, 2026-11-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates NPCE Hold at 4.5/10.
2 of the last 4 quarters beat the estimate; this quarter's -27.1% surprise compares with a +8.9% four-quarter average. Next scheduled report: 2027-03-02.
What argues against it
- Concentration risk — Product: RNS System
- Concentration risk — Supplier: single-source suppliers
- Market cap $260M below $400M minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.56
- Price target
- $13.24
- Stop
- $7.03
- Upside to target
- +75.1%
- Reward-to-risk
- 5.0:1
Risk check: RSI 20 — a level conventionally read as oversold; trading volume is running 14.4× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.
NPCE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $260.5M
- P/E (fwd)
- -25.4
- 52-week range
- $5.46–$19.60
- Off 52-week high
- 61.4%
- RSI (14)
- 20
- Volume vs avg
- 14.38×
- Score today
- 4.5/10